Business context and reporting period
Trinity Biotech plc filed this Form 6-K for October 2026 to report results of its annual general meeting held September 30, 2026. The report was signed October 5, 2026.
Financial performance and material changes
The filing reports no revenue, profit, cash flow, margin, debt, liquidity, or other financial results. It provides no comparison with a prior period.
Meeting results and management commentary
Shareholders approved all proposed resolutions, each with at least 95% of votes cast:
- Re-appointed Grant Thornton as statutory auditor until the conclusion of the next annual general meeting at which accounts are laid before the Company.
- Authorized the board to set the statutory auditor’s remuneration.
- Re-appointed Dr Andrew Omidvar as a director.
The filing provides no financial guidance, outlook, risk discussion, contingencies, or unusual items.
Important facts to verify
- Review the meeting notice dated September 4, 2026, for the full text of the resolutions.
- Confirm the auditor appointment and director reappointment in subsequent company disclosures.